8-K: Kestra's ASSURE WCD Shows Strong Effectiveness, Safety

Kestra Medical Technologies announced primary results from its ACE-PAS study, confirming the strong safety and 100% effectiveness of its ASSURE Wearable Cardioverter Defibrillator.

Summary

• Kestra Medical Technologies, Ltd. presented primary results from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) at the American Heart Association Scientific Sessions 2025.
• ACE-PAS is the largest prospective real-world study of wearable defibrillators to date, enrolling 21,612 patients across the United States from November 2021 through July 2025.
• The study confirmed the strong safety and effectiveness of the ASSURE Wearable Cardioverter Defibrillator (WCD) in clinical practice.
• The primary effectiveness endpoint was achieved with 100% successful conversion for ventricular tachycardia and fibrillation (VT/VF) events, surpassing the prespecified performance goal.
• The primary safety endpoint was met with an inappropriate-shock rate of 0.0065 per patient-month, which was below the prespecified performance goal.
• 94% of patients experienced no false positive shock alarms, contributing to patient confidence and comfort.
• 2.6% of patients experienced at least one life-threatening VT/VF event within a few months, underscoring the device's critical protection.
• The ASSURE system also detected high-rate atrial fibrillation in 4.2% of patients (35% previously undiagnosed) and severe bradycardia/asystole in 0.3%.
• Patients demonstrated high compliance, wearing the device for a median of more than 23 hours per day, with one-third continuing use beyond 90 days.

Sentiment

Score: 9

Explanation: The filing reports highly positive clinical trial results for the company's core product, the ASSURE WCD, demonstrating 100% effectiveness and a strong safety profile that surpassed prespecified goals. This is a significant validation of the product's performance in a large real-world study, which is crucial for market adoption and clinical guideline influence.

Positives

• 100% successful conversion for ventricular tachycardia and fibrillation (VT/VF) events, surpassing the prespecified performance goal.
• Inappropriate-shock rate of 0.0065 per patient-month, which was below the prespecified performance goal, confirming a strong safety profile.
• 94% of patients experienced no false positive shock alarms, enhancing patient confidence and comfort.
• The device provided critical protection, with 2.6% of patients experiencing at least one life-threatening VT/VF event within a few months.
• The ASSURE system facilitated detection of additional clinically relevant arrhythmias, including high-rate atrial fibrillation in 4.2% of patients (35% previously undiagnosed) and severe bradycardia/asystole in 0.3%.
• High patient compliance was observed, with a median wear time of over 23 hours per day and one-third of patients continuing use beyond 90 days.

Risks

• Risks related to the company's limited operating history and history of net losses.
• Ability to successfully achieve substantial market adoption of products.
• Competitive pressures in the medical device market.
• Ability to adapt manufacturing and production capacities to evolving demand, governmental actions, and customer trends.
• Potential for product defects or complaints and related liability.
• Ability to obtain and maintain adequate coverage and reimbursement levels for products.
• Ability to comply with changing laws and regulatory requirements and resulting costs.
• Dependence on a limited number of suppliers.
• Other risks and uncertainties described in the company's Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed July 17, 2025, and other periodic SEC reports.

Future Outlook

Additional analyses from the ACE-PAS study will be shared in forthcoming scientific forums. The compelling evidence from this study may help inform future updates to clinical practice, particularly regarding the identification and protection of patients at early risk of sudden cardiac death. The company aims to redefine wearable protection and advance evidence-based innovation by pairing proven performance with connected, data-driven insight.

Management Comments

• "ACE-PAS delivers robust, real-world evidence on how the ASSURE WCD performs in routine care and provides contemporary data describing the risk of life-threatening ventricular tachycardia and fibrillation in diverse populations with reduced cardiac function." Jeanne E. Poole, MD, Principal Investigator.
• "The ASSURE WCD should be considered to protect patients at elevated risk of sudden cardiac death during this vulnerable time." Jeanne E. Poole, MD, Principal Investigator.
• "These results reinforce the critical role wearable device monitoring and therapy can play in protecting patients during periods of elevated risk." Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies.
• "As the largest and most contemporary study of its kind, ACE-PAS provides compelling evidence that may help inform future updates to clinical practice—particularly around how physicians identify and protect patients at early risk of sudden cardiac death." Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies.

Industry Context

The announcement highlights the growing importance of wearable medical devices in cardiovascular disease management, particularly for patients at high risk of sudden cardiac death who may not yet qualify for permanent implantable devices. The study's large real-world dataset provides significant evidence that could influence clinical guidelines and reinforce the role of WCDs in patient care, aligning with a broader trend towards non-invasive monitoring and personalized medicine.

Comparison to Industry Standards

• The ACE-PAS study is noted as the 'largest prospective real-world study of wearable defibrillators to date,' suggesting it sets a new benchmark for the scale of evidence in this specific device category.
• The 100% successful conversion rate for VT/VF events surpasses the prespecified performance goal, indicating superior performance against internal or regulatory benchmarks.
• The inappropriate-shock rate of 0.0065 per patient-month was below the prespecified performance goal, demonstrating a strong safety profile compared to established safety targets for such devices.

Stakeholder Impact

• **Shareholders**: Positive clinical trial results are likely to increase investor confidence and potentially the company's share price, indicating strong product validation and market potential.
• **Patients**: The ASSURE WCD offers proven, effective, and safe protection against sudden cardiac death for vulnerable populations, potentially improving patient outcomes and quality of life.
• **Healthcare Providers**: The robust real-world evidence from ACE-PAS provides compelling data that may inform and update clinical practice guidelines, aiding physicians in identifying and protecting at-risk patients.
• **Regulators**: The post-approval study results reinforce the device's safety and effectiveness, potentially supporting its continued market presence and influencing future regulatory considerations for similar devices.

Next Steps

• Additional analyses from the ACE-PAS study will be shared in forthcoming scientific forums.
• The study results may help inform future updates to clinical practice, particularly regarding the identification and protection of patients at early risk of sudden cardiac death.

Key Dates

Recommendation

The filing presents exceptionally strong clinical trial results for Kestra's flagship ASSURE WCD, demonstrating 100% effectiveness in converting life-threatening arrhythmias and a safety profile that exceeded performance goals in the largest real-world study of its kind. These results significantly de-risk the product's market adoption and provide a strong foundation for future growth and potential updates to clinical practice guidelines. For a medical device company, such robust clinical validation is a critical driver of value and suggests a strong competitive position and future revenue potential, warranting a 'strong buy' recommendation.

Keywords

Wearable Cardioverter Defibrillator, WCD, ASSURE, Kestra Medical Technologies, ACE-PAS Study, Cardiac Arrhythmia, Sudden Cardiac Death, Medical Device, Clinical Trial Results, Cardiology, Heart Failure, Ventricular Tachycardia, Ventricular Fibrillation, Post-Approval Study